A Phase III Confirmatory Study of K-877 Extended Release Tablet
Status:
Active, not recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of K-877 Extended Release (ER) 0.2 mg/day or 0.4
mg/day (once daily) for 12 weeks in dyslipidemia, using K-877 Immediate Release (IR) 0.2
mg/day (twice daily) as a control.